U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849986) titled 'IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)' on Feb. 24.
Brief Summary: This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore the efficacy and safety.
Study Start Date: Feb. 25
Study Type: INTERVENTIONAL
Condition:
Soft Tissue Sarcomas
Angiosarcoma
Fibrosarcoma
Leiomyosarcoma
Pleomorphic Liposarcoma
Malignant Peripheral Nerve Sheath Tumor (MPNST)
Desmoplastic Small Round Cell Tumor
Intervention:
DRUG: Tislelizuma...